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Langerhans’s cell histiocytosis in old subjects: two rare case reports and review of the literature
Background: Langerhans cell histiocytosis (LCH) is a proliferative disease of histiocyte-like cells that
generally affects children; LCH onset is rare in adults; immunohistochemistry is essential to obtain the
correct diagnosis, and treatment protocols are controversial.
Objective: To describe two new cases of adult onset oral LCH.
Case reports: Case 1: a 71-year-old woman, complaining of diffuse oral pain, presented with erythem-
atous mucosal lesions; the panoramic radiograph and CT scan showed multiple mandible radiolucent areas.
Immunohistochemical assay for S-100, CD1a and langerin test was essential in reaching the correct
diagnosis. Case 2: a 77-year-old female patient presented with a non-painful, non-bleeding, slightly ele-
vated erythematous palatal lesion of 6 months duration, together with a genital vulvar lesion of uncertain
nature. The pathology confirmed the diagnosis of LCH. Many therapies (etoposid, radiotherapy) could
induce only a clinical partial remission; Cladribine induced a complete recovery.
Conclusion: The first case was difficult to diagnose: the clinical presentation and course of the disease
(LCH) in the elderly are multiple and unpredictable. An immunohistochemistry study is often essential to
obtain the correct diagnosis. The second case required several therapeutic interventions: even though some
cases regress spontaneously, others require systemic chemotherapy.
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Introduction
Among histiocytic disorders1–3, which include
a group of several diseases characterised by a
pathological proliferation and accumulation of
histiocytes (i.e. monocytes/macrophages, dermal/
interstitial dendritic cells, Langerhans cells) and
other immune effectors cells within multiple
tissues, Langerhans cell histiocytosis (LCH) is a
proliferative disease of histiocyte-like cells that
have been identified as Langerhans cells histiocytes
(LCHC), an immature dendritic cell that lacks the
ability to be a functional antigen-presenting cell3–5.
Even though the aetiology of the disease still
remains unclear, classically, this condition has been
described as a neoplastic process because of
the monoclonal proliferation of LCs, as LCHCs
expresses many LC antigens like S-100, CD1a and
langerin6–8; more recent studies highlight the
possibility that LCH is the result of an immune
dysregulation9–12.
Histologically, LCH is generally characterised by
immature LC proliferation accompanied by an
infiltrate of lympho-monocytes together with
eosinophilic and neutrophilic cells, which results in
the destruction of the affected tissues. As the
atypical cellular proliferation of LCHCs occur in
various organs and tissues (i.e. bone, liver, lungs,
lymph nodes, spleen, hematopoietic and mucocu-
taneous tissues), clinical manifestations might be
particularly different and complex6,10,11. For this
reason, the classical classification of the Histiocyte
Society into five different clinical types (eosino-
philic granuloma – localised disease, Letterer–Siwe
 2012 The Gerodontology Society and John Wiley & Sons A/S, Gerodontology 2012; 29: e1207–e1214 e1207
syndrome – systemic acute disease, Hand–Schu¨ller–
Christian syndrome – systemic chronic disease,
congenital self-healing LCH and pulmonary LCH)
should be replaced by the clinical classification of
the LCH study group, which divides LCH into sin-
gle-system LCH and multi-system LCH: the single
system is further subdivided into single site and
multiple site; the multi-system in low risk and high
risk according to the involvement of some organs
(liver, lungs, spleen, haematopoietic system)5,
high-risk patients presenting an higher mortality
rate.
A presumptive diagnosis of LCH may be made
based upon light microscopic findings, but a
definitive diagnosis requires that lesional cells
reveal positive staining with S-100, langerin and
CD1a or the identification of Birbeck granules upon
electron microscopy3. LCH generally affects child-
hood (peak incidence from 1 to 3 years), but a
report of the Histiocyte Society on late-onset LCH
was published stating that in these cases, the
diagnosis can be very difficult, and immunohisto-
chemistry techniques (S-100, CD1a and langerin)
can help in the differential diagnosis. The clinical
course of the adult onset LCH seems to be unpre-
dictable, but in many cases, it regresses spontane-
ously or after adequate therapy12–14.
This report describes two cases of LCH with oral
involvement detected in two elderly female
patients (71 and 77 year olds, respectively).
Case reports
Case 1
A 71-year-old Caucasian woman, complaining of
diffuse oral pain, was referred by her dentist to our
Clinic (October 2003). She reported mouth and
gingival discomfort since the beginning of 2001,
when she went to her dentist to be treated. Her
dentist considered the pain as a pulpitis and decided
to perform a root canal of the left superior canine
and the first lower right molar (teeth number 2.3
and 4.6). As the symptoms did not disappear
(November 2002), a panoramic radiograph was
requested (Fig. 1a): a periapical radiolucency of the
lower left first molar and of the lower right second
molar (teeth number 3.6 and 4.7) and a diffuse
periodontal disease (mostly related to maxilla)
were noticed. The dentist extracted the first upper
left molar (tooth number 2.6) affected by severe
periodontal disease and did a root canal of first left
lower molar (tooth number 3.6). Few months later,
as the symptoms were still present, the dentist
asked for a new radiograph from which some new
radiolucent areas, mainly located in the left man-
dible, could be noticed (Fig. 1b).
At this point (October 2003), the patient was
referred to our Clinic. During the first interview,
the patient reported to be suffering from a Wolf–
Parkinson–White syndrome and from mild hyper-
tension and was treated with ACE inhibitors. No
other relevant information was collected on the
medical history. The oral examination revealed
chronic periodontal disease (vertical and horizontal
bone loss), furcation involvement on teeth number
3.6 and 4.6 and endo-perio pathologies, but all
(a)
(b)
(c)
(d)
Figure 1 Case 1 – Radiological findings. (a) First pano-
ramic radiograph (November 2002) showing a periapical
radiolucency of the lower left first molar and of the lower
right second molar (teeth number 3.6 and 4.7) and a
diffuse periodontal disease (mostly related to maxilla).
(b) Second panorex, performed few months later, show-
ing some new radiolucent areas, mainly located in the
left mandible: the lesions were multiple, but uniloculate
with well-defined margins, but without any sclerotic
reactive halo. (c) CT scan section shows many diffuse
osteolytic lesions in the cancellous bone of the mandib-
ular body. (d) Cross-section showing a detail of the left
mandible: the lingual cortical plate is perforated.
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teeth were stable and non-mobile. On the upper
left palate and on the upper left edentulous ridge,
an erythematous mucosal lesion was present, with
undefined margins and areas of ulceration
(Fig. 2a); other smaller ulcers were present on the
gingival mucosa (from lower right lateral incisor –
tooth number 4.2 – to lower right second premolar
– tooth number 4.5 – Fig. 2b). Routine blood tests
were all normal. A biopsy from the edentulous
ridge of the palate was performed, and the
pathology revealed a subepithelial blastic infiltrate:
(a)
(b)
Figure 2 Case 1 – Clinical presentation. (a) Intraoral
examination revealed an erythematous mucosal lesion
on the upper left palate and on the upper left edentulous
ridge: the lesions had undefined margins and were not
elevated, presenting areas of ulceration, non-bleeding
and slightly sore. (b) Some well-defined smaller ulcers,
surrounded by an erythematous halo, were present on
the gingival mucosa (from tooth – 4.2 – to lower right
second premolar – 4.5).
(a)(b)
(c)(d)
(e)
(f)
Figure 3 Case 1 – Pathological features and immuno-
histochemical assay. (a) Low-power magnification of the
palatal biopsy revealed a subepithelial inflammatory
infiltrate (EE 25·). (b) In higher magnification, a blastic
inflammatory cell infiltration can be noted: blastic cells
with nuclear atypias, mitoses and eosinophilic cytoplasm
can be seen (EE 200·). (c) Pathology revealed a complete
change of the bone tissue pattern: a diffuse inflammatory
infiltrate can be noted (EE 50·). (d) In higher magnifi-
cation, plasmacytic-like cells with nuclear atypias, hy-
perchromic nuclei in eccentric position and eosinophilic
cytoplasm replaced the normal bone tissue (EE 200·). (e)
Immunohistochemical staining for langerin on bone
tissue (200·). (f) Immunohistochemical staining for
langerin on palatal mucosa (25·).
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immunohistochemistry staining was negative for
lymphoid markers (CD34 and keratins) and posi-
tive for myeloid markers, thus suggestive of a
myeloid proliferative disease (Fig. 3a, b), but the
bone marrow biopsy was negative. CT scan of the
jaws showed diffuse osteolytic lesions, mainly
located in the left mandible; these lesions were well
defined, and in some areas, the mandibular cortical
bone showed perforations (Fig. 1c, d).
There were many aspects that did not make
sense. In particular, the faint and shifty nature of
the symptoms, which characterised the history
of this patient, did not correlate with the ‘severity’
of the pathology report. Furthermore, blood exams
and the bone marrow biopsy excluded any hae-
matological disease.
In a further appointment (beginning of 2004),
we completely re-evaluated the case, and during a
thorough medical history interview, the patient
reported that she was also suffering from diabetes
insipidus for approximately 6 years and she was on
desmopressin. Then, a bone biopsy of the man-
dibular lesions was performed (February 2004),
and the pathology report revealed a complete
change of the bone tissue pattern; plasmacytic-like
cells with nuclear atypias, hyperchromic nuclei in
eccentric position and eosinophilic cytoplasm were
infiltrating the bone. Mitosis was also present
(Fig. 3c, d). Immunohistochemical assay to rule out
LCH (S-100, CD1a and langerin) was positive
(Fig. 3e); all markers were also positive on the
previous biopsy of the palatal mucosa (Fig. 3f);
total body CT scan excluded other organs involved.
Systemic chemotherapy was performed, consisting
of vinblastine (10 mg) and prednisone (60 mg) I.V.
in six weekly courses, followed by additional six
courses performed every 2 weeks; zoledronic acid
(6 monthly doses of 4 mg) was also administered.
Following this treatment, the patient had complete
resolution of the oral symptoms and lesions; ste-
roids were tapered slowly with a small mainte-
nance dose (10 mg/day) for 6 months. No further
relapses were detected thus far.
Case 2
In April 2004, a 77-year-old Caucasian woman was
referred to the Dental Clinic of the University of
Palermo with a non-painful and non-bleeding
palatal swelling for about 6 months duration. At
the same time, the patient complained a genital
vulvar lesion of unknown nature.
The medical history revealed type II diabetes
mellitus diagnosed 5 years earlier and treated with
gliclazide 30 mg once daily and high blood pressure
treatment for the past 15 years, treated with
chlortalidone 12.5 mg plus atenolol 50 mg once
daily; no smoking or drinking habits.
The intraoral examination revealed two distinct
lesions (Fig. 4): a slightly elevated erythematous
plaque in the right palate (1.5 · 4 cm), tender–
elastic in consistency with irregular margins, non-
painful and not bleeding; the second one, in the left
palate, was dark reddish, two centimetres in
diameter, tender elastics in consistency, non-
bleeding. Panoramic radiograph and a CT scan as
Figure 4 Case 2. Clinical presentation. Two main lesions
can be noted: the right palate and the right maxillary
edentulous ridge presented a slightly elevated reddish
plaque (1,5 · 4 cm), tender–elastic in consistency with
non-defined margins, non-painful and non-bleeding; a
dark reddish, two cm in diameter, tender elastics in
consistency, non-bleeding lesion can be seen in the left
palate.
(b)
(a)
Figure 5 Case 2. Pathological feature. (a) Low-power
magnification: subepithelial acute inflammatory infil-
trate (EE 25·). (b) In higher magnification, eosinophils
together with localised areas of mononucleate hyper-
plastic cells with cleft nuclei can be noted (EE 100·).
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well as serologic tests (routine blood tests and
rheumatoid factor, anti-streptococcus titre, HBV
and HCV antibodies) were all non-contributory.
The incisional biopsy of the right lesion revealed an
acute inflammatory infiltrate, mainly consisted of
eosinophils clustered together with localised areas
of mononuclear hyperplastic cells with cleft nuclei.
The pathology was consistent with LCH (Fig. 5).
A bone triphasic scintigraphy and a whole-body
single-photon emission tomography revealed the
presence of some areas of a tracer uptake in the
right maxilla, but no further bone pathological fo-
cal lesions were detected. An abdominal ultrasound
did not reveal any abdominal abnormalities. After
4 months of follow-up, the clinical appearance did
not change, so a steroid therapy (prednisone 25 mg
once daily) was started. After 1 month of steroid
therapy, the lesions did not show any improve-
ment, so the patient was referred to the haema-
tology department. The haematologist, as no bone
lesions were present, proposed six cycles of che-
motherapy with etoposide (100 mg once daily) and
dexamethasone (0.5 mg once daily) for three con-
secutive days every 3 weeks. Routine blood tests
(blood count test, azotemia, cretininemia, urice-
mia, glycaemia, transaminases, bilirubin) were
carried out before every cycle, and a co-therapy
with sulfamethoxazole 800 mg plus trimethoprim
160 mg bid and pantopazole 20 mg once daily was
administered for 7 days.
After 2 cycles (September 2004), the clinical
presentation improved and the patient decided to
undergo only two further cycles (only four cycles
instead of 6). Two months after the 4th cycle
(January 2005), a new biopsy was performed on
the residual lesions showing a necrotizing vasculi-
tis; the patient showed a clinical partial remission
for 5 months (May 2005), when a relapse was
discovered and confirmed by biopsy. After some
months of follow-up, radiotherapy was performed
(November 2005), and the clinical presentation
improved and remained stable for 1 year, when a
further oral and vaginal relapse occurred (April
2006). A vaginal biopsy confirmed the relapse of
the disease. At that time, a head and neck Magnetic
Resonance Imaging (MRI) revealed bilateral intra-
parenchymal parotid lesions (max. diameter
2.5 cm), and therefore, a further chemotherapy
with cladribine was performed for a total daily dose
of 10 mg for five consecutive days (0.14 mg/Kg/
day). After two cycles, a regression of the oral sal-
ivary glands (MRI documented) and vaginal lesions
was seen, but it was necessary to diminish the dose
because of a systemic toxicity. The third cycle
(8 mg daily) caused severe neutropenia (2730
white blood cells/ll of which 1569 neutrophils)
and anaemia (9.3 g/dl), and it was necessary to
support the patient with g-CSF (filgrastim) and
three transfusions. The 4th cycle (7 mg daily) was
well tolerated, but an oral candidosis arose and it
was treated with miconazole 2% oral gel. After the
4th cycle, a complete recovery was obtained, and
no other relapses showed up so far.
Discussion
Clinical–pathological correlations and the onset in
older adults made the diagnosis of LCH and the
clinical management interesting and difficult at the
same time. The first case had a difficult time to
diagnose, whereas the second one, easier to diag-
nose, required several therapeutic interventions,
showing several relapses.
First of all, considering the epidemiology of LCH,
our cases differ from usual distribution of the dis-
ease: LCH affects mainly children (5 per million),
whereas in our case, it arose in two adult women,
71 and 77-year olds, respectively (1–2 adults af-
fected per million and even fewer on adults older
than 60 years of age)6. According to the report of
the International Registry of the Histiocyte Society
on adult LCH (IRHSA), which studied the clinical
characteristics of 274 cases from 13 nations, the
mean age of the first manifestation in adults was
33 years with a peak between 20 and 30 years and
only few records refer to people older than
60 years; considering all cases diagnosed through a
biopsy (253 subjects), in the majority of cases, it
was performed on bone (38.8%), whereas only in
few cases, it was performed on mucosal membranes
(3.9%): in our second case, the mucosal biopsy was
sufficient to reach a correct diagnosis, but a further
jaw bone biopsy was necessary for the correct
diagnosis in the first one. Considering clinical
manifestation of adult patients suffering from a
multiple organ involvement (188 subjects) pre-
sented in the IRHSA, bone (66.0%), skin (50.5%)
and lung (61.7%) lesions, together with diabetes
insipidus (43.1%), were the most frequent symp-
toms, and, because of the rarity of the disease, the
median latency time was 4 months (interquartile
ranges – 0 to 22 months); patients presenting with
isolated diabetes insipidus had a median latency
time in diagnosis of 11 months (interquartile ran-
ges – 0–48)6,12–14. In our first case, the patient did
not report diabetes insipidus during the first med-
ical interview neither we further investigated the
matter which could have addressed the diagnosis
towards a wider group of systemic diseases. In any
case, the latency time was almost 4 years since she
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was diagnosed with diabetes insipidus and
5 months since the patient was referred to our
Clinic.
Langerhans cell histiocytosis in general can affect
all hard and soft tissues of the oral and maxillofacial
region (gingiva, floor of the mouth and palatal
mucosa, the sinus cavity), presenting as unifocal
single-system disease in about 50% of maxillofacial
LCH. The mandibular bone, especially in its posterior
region, seems more frequently affected (three times
more than maxilla). Clinical appearance can vary
from intraoral mass to gingivitis, loose teeth, oral
ulcers with impaired healing, whereas tooth
displacement and root resorption are seen less fre-
quently14–16. The oral clinical presentation of the
first case was faint and shifty: the patient reported
only an initial diffuse oral discomfort, mainly char-
acterised by diffuse periodontal symptoms that,
considering the age of the patient, were first attrib-
uted to chronic periodontal disease (diffuse hori-
zontal and vertical bone loss). The presence of bone
radiolucencies far from periodontal structures, to-
gether with the finding of the diabetes insipidus
during the second collection of her medical history,
brought up the question of a possible multi-system
disease. In this case, radiolucencies were multiple,
uniloculate and well defined, not specific of LCH:
such radiolucencies can be seen in many other dis-
eases such as metastases, osteomielitis or malignant
haematological tumours as multiple myeloma, but,
in our case, blood exams and bone marrow biopsy
excluded any other haematological diseases. The
clinical presentation of the second patient was easier
as she was edentolous in the affected area, a vulvar
contemporary lesion was present and the first
mucosal biopsy was diagnostic.
Generally speaking, pathology is characterised by
LCHCs, T-cell lymphocytes, eosinophils and mac-
rophages: LCHCs are characterised by an abundant
eosinophilic to amphophilic cytoplasm, reniform
nucleus, deeply indented or grooved; mitosis are
rare. The number of eosinophils is quite variable
from rare to predominant giant cells, and necrosis
can be present in the granulomatous process. The
clinical–pathological correlation was essential to
reach the correct diagnosis in the second case, but
was not sufficient in the first case, where immu-
nohistochemistry played a fundamental role.
Among the possible antigens, recently, a highly
specific and sensitive monoclonal antibody against
CD207 (langerin) is available. This protein seems
important in the formation of the Birbeck-Broad-
bent granules, which are always present in LCH
and can be detected through ultrastructural study
making the diagnosis certain6,7,17,18.
In the last years, many molecular aspects of the
disease were better understood, suggesting the
possibility that LCH could be the result of an
immune dysregulation9–12: many pro-inflamma-
tory chemokines (CCL20, CCL2, CCL3, CCL4,
CCL5, CXCL8, CXCL10) can be released by LCH,
which contribute to the recruitment of other
inflammatory cells. Through autocrine and para-
crine mechanisms, these molecules contribute to
the onset and maintenance of the lesions. The re-
cruited cells (Lymphocyte, macrophages and eo-
sinophils) contribute themselves to this process
producing many other cytokines (IL-1, IL-3, IL-4,
IL-5, IL-8, IL-10, TNF-a). This particular immuno-
logical setting, called ‘cytokines storm’, can explain
many clinical local and systemic symptoms as fever,
pain, osteolysis, anaemia, fatigue, lymphadenopa-
thy, etc. On the other hand, many genetic abnor-
malities (i.e. loss of heterozygosity, damages of
chromosomes 1, 7, 9, 17, damages of genes IDE,
PAN, PAX7, E2F2, TNFR-2, TCEB, cyclin-depen-
dent kinases, cyclin-dependent kinases inhibitors,
p14, p15, p16, p53, NF2, c-myc, h-ras) were de-
tected in LCH during the last decade, supporting
the possible clonal-expansive nature of the disease.
Both these molecular pathways are now under
investigation as possible targets for molecular
therapy (i.e. gene therapy, monoclonal antibodies,
immunomodulators)6–11,19–22.
The treatment protocol, which was really
demanding in the second case, must consider the
general stadiation of the disease (single-system vs.
multi-system; single-site vs. multiple-site) and can
vary from local surgery to radiotherapy to chemo-
therapy11. The Histiocyte Society performed three
major study protocols for paediatric LCH (LCH-I,
LCH-II and LCH-IIII), and, more recently, a proto-
col for adult onset was started, considering vin-
blastine plus prednisone for multisystem disease,
but the therapy regimen for adult still remains
dubious: it can vary from watchful waiting to local
therapy (surgery and radiotherapy) to systemic
chemotherapy in the refractory cases (i.e. cladri-
bine, thalidomide, vinblastine, steroids)6,23–27. In
our second case, many relapses occurred after local
or mild systemic therapies: at the end, the admin-
istration of cladribine was necessary to control the
disease.
In an interesting article, Bartnick reviewed 12
cases of oral LCH and proposed a new classification
for oromaxillofacial region (OMF-LCH), which can
suggest a prognostic–therapeutic approach for cli-
nicians and should be used for research purpose:
stage I with single maxillofacial lesion, Stage II with
multiple maxillofacial lesions and Stage III with
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oromaxillofacial lesions plus other regions. For
each stage three different sublevels are possible: (i)
only bone lesions, (ii) only soft tissues and (iii)
additional visceral involvement. According to this
classification, the first case was oromaxillofacial
region (OMF-LCH) stage III, sublevel C, whereas
the second case was oromaxillofacial region (OMF-
LCH) stage III, sublevel B, both cases requiring an
aggressive therapeutic approach15. A further clas-
sification, which take into consideration both
OMF-LCH15 and LCH study group classification5,
could help clinicians in addressing the more suit-
able therapeutic regimen and in forecasting the
prognosis.
Conclusion
Langerhans cell histiocytosis (LCH) is a proliferative
disease of histiocyte-like cells and generally affects
childhood (peak incidence 1–3 years). Adult onset
LCH is rare, especially in the elderly; often immu-
nohistochemistry techniques (S-100, CD1a and
langerin), as we showed in our first case, are
essential to reach the correct diagnosis, as the
clinical presentation and course of the disease are
often multiple and unpredictable; there is still no
consensus on therapeutic protocols and several
relapses could occur, as happened in our second
case: the presence of oromaxillofacial lesions could
give good prognostic–therapeutic information for
clinicians.
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